Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) with Dasatinib and Venetoclax: A Phase II Study

The goal of this clinical research study is to learn if giving half of the recommended FDA approved dose of dasatinib can help to control CML as effectively as the full dose of dasatinib. Researchers also want to learn if combining venetoclax with dasatinib after 3 months of dasatinib alone is helpful in controlling CML compared to dasatinib alone. The safety of the combination will also be studied.

Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic

Treatment Agent: Dasatinib

Treatment Location: Only at MDACC

Sponsor: BMS

IRB Review and Approval Date: 02/19/2016

Recruitment Status: Open

Projected Accrual: N/A

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT02689440